Endotoxins, small moleculespresent in bacterial membranes, pose a risk of contamination in biologicalproducts.  If not cleared during themanufacturing process, tissue injury, fever, septic shock or death can occur ifinjected into mammals.  With bothclinical and commercial manufacturing, steps and technologies must be developedto clear this impurity from pharmaceutical products.  Here, commercially available technologies areevaluated and compared for pre-clinical protein production.

Evaluation of endotoxin removal technologies

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.